Docs concerned for the use of Favipiravir for COVID in India


By MYBRANDBOOK


Docs concerned for the use of Favipiravir for COVID in India

Favipiravir, an antiviral drug for the treatment of mild-to-moderate COVID-19 cases, was launched recently by Glenmark Pharmaceuticals. According to reports, the drug has been launched after it received approval from the Drug Controller General of India to manufacture and market the medicine.

 

The antiviral drug Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It works by inhibiting viral replication and reducing the viral load in a patient. It is an experimental medicine being repurposed for COVID-19.

 

According to Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals the approval has come at a time when cases in India are spiralling, putting tremendous pressure on our healthcare system.

 

The drug FabiFlu will be available as a prescription-based medication for Rs 103 per tablet, with the recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.

 

The drug is not recommended in patients with severe renal, hepatic impairment, and in pregnant and lactating women.

 

Glenmark has claimed that Favipiravir shows clinical improvements of up to 88% in COVID-19 disease, with a rapid reduction in viral load by 4 days.

 

Favipiravir is being studied in at least 18 trials around the world as a potential treatment for COVID-19. Earlier last month, Glenmark also announced that it is conducting another clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India.

 

But according to doctors there is insufficient evidence in favour of the medicine. A large portion of doctors don’t feel there is any real requirement of the medicine for mild attacks. They feel there is so much panic and fear around the disease that they will be forced to arrange for the medicine even if they have no funds - when in reality, a mild COVID case may recover either without medication, or with medicines costing no more than Rs 10.

 E-Magazine 
 VIDEOS  Placeholder image
 STARNITE AWARDS 2024  

 ITFORUM 2024  

   



 CMO of the Year   Placeholder image

 WOMEN LEADERSHIP  Placeholder image

 EMINENT CIO's OF INDIA   Placeholder image

 TRENDS IN TECHNOLOGY  Placeholder image

MORE VIDEOS  Placeholder image
 ADVERTISEMENTS  Placeholder image
Brandbook Brandbook

 TECHNOLOGY DISRUPTION Placeholder image


 UNICORNS REVOLUTIONISING Placeholder image



Copyright www.mybrandbook.co.in @1999-2024 - All rights reserved.
Reproduction in whole or in part in any form or medium without express written permission of Kalinga Digital Media Pvt. Ltd. is prohibited.
Other Initiatives : www.varindia.com | www.spoindia.org